Air Force veteran Melissa Hay battled years of misdiagnosis before discovering she had Fabry disease—a rare, life-threatening ...

Sangamo Therapeutics Inc (SGMO) reports significant milestones and strategic initiatives, despite financial challenges, in ...

PLX READ THE FULL PLX RESEARCH REPORT First Quarter 2025 Financial and Operational Review Protalix Biotherapeutics, Inc. (NYSE:PLX) announced 1Q:25 financial and operational results in a May 9th, 2025 ...

Announced derisking milestones in pathway to anticipated biologics license application (BLA) submission for isaralgagene civaparvovec in Fabry disease, including all patients having passed one-year ...

In the first quarter of 2025, the Company completed a public offering of 5.1 million ordinary shares, including the full exercise of the underwriters' overallotment option, at a public offering price ...

A "productive" meeting with the FDA has given the firm confidence in its regulatory filing and commercialization plans for ST-920.

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease ...

Amicus Therapeutics FOLD reported first-quarter 2025 adjusted earnings of 3 cents per share, which missed the Zacks Consensus Estimate of 8 cents. The company had reported a loss of 2 cents per share ...

With a disease as difficult and devastating as Alzheimer's disease, we want to do everything we can to delay and prevent progression. Not everything marketed for memory and other symptoms of the ...

He has learned to love just about every genre of game that exists. There are a lot of diseases in The Elder Scrolls 4: Oblivion Remastered. You’ll pick up diseases from things like enemy attacks ...

A research facility within the US National Institutes of Health that is tasked with studying Ebola and other deadly infectious diseases has been instructed by the Trump administration’s ...

An approval decision for Stealth BioTherapeutics’ investigational treatment for an ultra-rare genetic disease has been delayed—again—this time, with no new decision date given. The biotech ...